In NSCLC cells, IL-6 neutralizing antibodies have been shown to inhibit tumor growth in mouse transplanted tumor models by inhibiting JAK1/STAT3 signaling (Song et al., 2011). This evidence concerns the gene JAK1 and neoplasm.